Teva and medincell announce fda approval of uzedy™ (risperidone) extended-release injectable suspension, a long-acting subcutaneous atypical antipsychotic injection, for the treatment of schizophrenia in adults

Parsippany, n.j., tel aviv & paris--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), and medincell (euronext: medcl) announced today that the u.s. food and drug administration (fda) has approved uzedy (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. uzedy is the first subcutaneous, long-acting formulation of risperidone that utilizes steadyteq™, a copolymer technology proprieta.
TEVA Ratings Summary
TEVA Quant Ranking